Sugi Predict

Sugi Predict / Targets / EP300

EP300

Histone acetyltransferase p300 · Q09472 · EP300 on Sugi Atlas →

100,383 patent compounds predicted against EP300, 62,521 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL140792 SCHEMBL140792 0.38 8/20
SCHEMBL152213 SCHEMBL152213 0.34 8/20
Berberine Berberine (SCHEMBL153906) 1.00 7/20
SCHEMBL198012 SCHEMBL198012 0.49 7/20
Berberine Berberine (SCHEMBL25632) 1.00 6/20
Gliotoxin Gliotoxin (SCHEMBL54420) 0.45 6/20
SCHEMBL22657 SCHEMBL22657 1.00 5/20
Berberine Berberine (SCHEMBL94112) 0.90 5/20
SCHEMBL78329 SCHEMBL78329 0.62 5/20
SCHEMBL77020 SCHEMBL77020 0.50 5/20
SCHEMBL77021 SCHEMBL77021 0.50 5/20
SCHEMBL76034 SCHEMBL76034 0.47 5/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL156132) 0.42 5/20
Coenzyme_A Coenzyme_A (SCHEMBL88057) 0.88 4/20
SCHEMBL60436 SCHEMBL60436 0.83 4/20
SCHEMBL107144 SCHEMBL107144 0.83 4/20
SCHEMBL168546 SCHEMBL168546 0.81 4/20
3-Hydroxy-3-Methylglutaryl-Coenzyme A 3-Hydroxy-3-Methylglutaryl-Coenzyme A (SCHEMBL1198) 0.79 4/20
SCHEMBL188195 SCHEMBL188195 0.78 4/20
SCHEMBL188145 SCHEMBL188145 0.75 4/20

Clinical trials — most relevant to EP300 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer PHASE2UNKNOWN
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma PHASE2COMPLETED
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma PHASE2COMPLETED
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia PHASE1/PHASE2ACTIVE_NOT_RECRUITING
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS PHASE2COMPLETED
Enhancement of in-Vitro GC Function in Patients With COPD PHASE2COMPLETED
Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer PHASE2COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies PHASE1RECRUITING
Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours PHASE1COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors PHASE1COMPLETED
A Study of CS3006 in Subjects with Locally Advanced or Metastatic Solid Tumors PHASE1COMPLETED
A Phase I Study of GT300 in Healthy Subjects PHASE1UNKNOWN
Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia PHASE1COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia nanRECRUITING
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
Epigenetics in the Aging Process nanCOMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a EP300 binder may also engage these)

ProteinNameSimilarity
B2RWS6 — 1.000 B2RWS6 →
CREBBP CREB-binding protein 1.000 landscape →
Q6JHU9 — 0.998 Q6JHU9 →
P45481 — 0.997 P45481 →
Q14686 — 0.994 Q14686 →
Q9JL19 — 0.992 Q9JL19 →
P34545 — 0.991 P34545 →
BCL9 B-cell CLL/lymphoma 9 protein 0.990 landscape →
Q21955 — 0.990 Q21955 →
Q9Y149 — 0.990 Q9Y149 →
B2C6R6 — 0.990 B2C6R6 →
Q15714 — 0.989 Q15714 →
Q172Y1 — 0.988 Q172Y1 →
Q4V3C1 — 0.987 Q4V3C1 →
Q63627 — 0.987 Q63627 →
F4I171 — 0.987 F4I171 →
P62501 — 0.987 P62501 →
Q9P2D1 — 0.987 Q9P2D1 →
O95104 — 0.987 O95104 →
Q9JLI4 — 0.987 Q9JLI4 →
Q91012 — 0.986 Q91012 →
Q5R4H1 — 0.986 Q5R4H1 →
Q6DDH6 — 0.986 Q6DDH6 →
P40645 — 0.986 P40645 →
A5D7F6 — 0.986 A5D7F6 →
Q7ZUK7 — 0.986 Q7ZUK7 →
P0CB49 — 0.986 P0CB49 →
Q5TP13 — 0.986 Q5TP13 →
Q6EUW2 — 0.985 Q6EUW2 →
Q5RCU4 — 0.985 Q5RCU4 →